How Dividend Aristocrats Are Quietly Outperforming in 2026

In this episode of The Quarterly Review, Lucas and Luna dig into an earnings-season pattern that's easy to miss: dividend aristocrats are quietly beating the market. With the S&P 500 up nearly 3% in five days and the NASDAQ surging 3.8%, the usual tech narrative dominates, but a closer look at the numbers shows a different story. They discuss how a 1.5% real GDP growth reading—down from 2.1%—is pushing investors toward stability, and why dividend payers like Pfizer, up 3.5% this week, are gaining favor. The hosts explore the mechanics of dividend growth, the historical outperformance of these stocks during slower growth periods, and how the current economic signals are reinforcing a shift toward income-focused investing. They also touch on the risk of overhyping safety and what to watch for in the next few quarters. If you're wondering whether dividend stocks deserve a spot in your portfolio, this conversation offers a grounded, data-driven perspective. #DividendAristocrats #EarningsSeason #GDPGrowth #Pfizer #SAndP500 #NASDAQ #IncomeInvesting #DividendGrowth #MarketOutlook #ValueStocks #EconomicSlowdown #StableInvesting #FinancialAnalysis #Business #Finance #FexingoBusiness #BusinessPodcast #QuarterlyReview Keep every episode free: buymeacoffee.com/fexingo